AKT1 and Bloom syndrome: Similarly, pirfenidone, a PARK2 promoter, was observed to induce autophagy and inhibit myofibroblast differentiation by inducing PARK2 expression and reducing PDGFR-PI3K-Akt activation in BLM-treated WT mice, but not in PARK2 KO mice 104.